Search the Newsreel

CON: Q2 2026 delivered robust revenue and EBITDA growth, with raised full-year guidance and lower leverage

Concentra Group Holdings (CON) reported strong Q2 2026 results, showing double-digit revenue and Adjusted EBITDA growth, along with margin expansion and increased volumes in core services. The company also raised its full-year guidance for revenue, EBITDA, and free cash flow, achieving its leverage targets …

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside

CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 …

Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the …

ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary

ALX Oncology Holdings Inc. reported a reduced net loss of $17.97M in Q2 2026, down from $25.95M in Q2 2025, with diluted EPS improving to $(0.13) from $(0.49). This improvement is attributed to lower operating expenses resulting from streamlined clinical programs. The company highlighted …

Earnings call transcript: Once Upon a Farm lifts 2026 outlook after Q2 sales surge

Once Upon a Farm (OFRM) announced a strong Q2 2026 performance with a 42.3% sales increase to $85.4 million and narrowed its net loss, leading to raised full-year guidance for revenue and adjusted EBITDA. The company saw its stock rise in after-hours trading as …

Concentra Q2 2026 earnings: Operating leverage lifts profit and cash flow

Concentra (NYSE: CON) reported a strong Q2 2026, with revenue up 10.0% to $606.0 million and diluted EPS rising to $0.51 from $0.35. The company benefited from operating leverage, as costs grew slower than revenue, leading to a 46.5% increase in net income and …

Form 8K Oncology Institute Inc For: 6 August By Investing.com

The article reports on an 8K filing by Oncology Institute Inc. for August 6. It includes a stock market publication timestamp and references the company's stock symbol STLN. The content also features various market data, trending stocks, and related news headlines.

Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance

Matt DiCanio to become president and CEO and Keith Newton to transition to executive chairman, effective Nov. 1, 2026 DALLAS, August 06, 2026--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. ("Concentra", the "Company", "we", "us", or "our") (NYSE: CON), the nation's largest provider of occupational health …

Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales

Ambaw Bellete, an insider at CG Oncology, Inc. (NASDAQ: CGON), has filed to sell 75,000 shares of common stock through Morgan Stanley's Executive Financial Services program, linked to a stock option exercise on August 6, 2026. This proposed sale has an aggregate market value …

CG Oncology earnings up next amid bladder cancer therapy push By Investing.com

CG Oncology Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss as the company progresses towards a regulatory filing for its bladder cancer treatment. The biotech aims to complete its Biologics License Application by Q4 2026, positioning it for potential …

3 Healthcare Stocks Retail Investors Are Watching As Hiring Slows

The article highlights three healthcare stocks—Krystal Biotech (KRYS), BeOne Medicines (ONC), and Zevra Therapeutics (ZVRA)—that retail investors are watching due to resilient hiring and growth in the healthcare sector despite a general slowdown in private sector job creation. It provides an overview of each …

Concord Biotech Limited Just Beat Revenue Estimates By 5.0%

Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aktis Oncology (NASDAQ:AKTS) has received a consensus "Moderate Buy" rating from eight analysts, with an average 12-month price target of $34.60. The company reported quarterly revenue of $3.23 million, surpassing estimates, though its loss per share slightly missed expectations. Insider trading activity included a …

Neo-Concept International Group Holdings Limited Class A (NCI) Live Share Price, Invest From India

This article provides detailed financial information for Neo-Concept International Group Holdings Limited Class A (NCI), including its live share price, performance metrics, fundamentals, valuation, and peer comparisons. It also offers insights for Indian investors on how to invest in NCI shares and highlights recent …

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock …

Earnings Flash (CON) Concentra Group Holdings Parent, Inc. Posts Q2 Adjusted EPS $0.52 per Share, vs. FactSet Est of $0.42

Concentra Group Holdings Parent, Inc. reported Q2 adjusted EPS of $0.52 per share, surpassing the FactSet estimate of $0.42. The company also announced an increase in its 2026 revenue guidance, board changes, and the appointment of Matt DiCanio as CEO.

FMR LLC discloses 9.4% Concentrix (CNXC) ownership in amended Schedule 13G

FMR LLC has filed an amended Schedule 13G, reporting beneficial ownership of 5,712,933.85 shares of Concentrix Corp (CNXC) common stock, which represents 9.4% of the class. Abigail P. Johnson also reports the same beneficial ownership. FMR LLC holds sole voting power over 5,712,076.00 shares …

Concentrix Corporation (CNXC) Stock Forecasts

This article provides a brief overview of Concentrix Corporation (CNXC), describing it as a technology-enabled company specializing in customer engagement and management. It highlights an Argus research report from August 5, 2026, offering a rating and current price of $25.72 for CNXC, and encourages …

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) reported a Q2 loss of $0.9 per share, missing the Zacks Consensus Estimate of a $0.7 loss, and posted revenues of $1.16 million, which fell short of estimates by 59.02%. Despite the earnings miss, the company's shares have risen 74.4% …

Earnings Flash (CGON) CG Oncology, Inc. Reports Q2 Revenue $1.2M

Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.34 per share and revenue of $33,000, continuing a trend of projected annual losses of around $1 per share. Despite mixed …

CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its clinical programs, including the ASPEN-09-Breast trial for evorpacept and the Phase 1 trial for ALX2004. The company reported a strengthened balance sheet, with cash …

Concrete Pumping (NASDAQ:BBCP) Rating Lowered to "Hold" at Zacks Research

Zacks Research has downgraded Concrete Pumping (NASDAQ:BBCP) from "strong buy" to "hold" following the company's recent earnings report where it missed EPS estimates but exceeded revenue expectations. Despite the downgrade, the broader analyst consensus remains a "Moderate Buy" with a $10.25 target price. Insiders …

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 …

CG Oncology expects bladder cancer trial data soon; cash through 2029

CG Oncology reported a Q2 2026 net loss of $79.1 million on $1.2 million in revenue, primarily due to increased R&D and G&A expenses. The company maintains a strong cash position of approximately $1.0 billion, which is projected to fund operations through 2029, supporting …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pyxis Oncology Inc (PYXS), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 10 analysts have given the stock a "Buy" trend, with an average price target of $7.70. The article …

Ponce Financial Group, Inc. Q2 2026: Net income $8.21M, EPS $0.35— 10-Q Summary

Ponce Financial Group, Inc. reported strong Q2 2026 results with net income increasing to $8.21M, a 41.2% year-over-year change, and diluted EPS rising to $0.35. This growth was primarily driven by a significant increase in net interest income and margin expansion, alongside strategic shifts …

UBS Group raises BeiGene (ONC.US) target price to $467, citing another earnings beat in the second quarter and naming it a top pick.

UBS Group has raised its target price for BeiGene (ONC.US) to $467, following the company's strong second-quarter earnings performance. The firm reiterated its "Buy" rating and named BeiGene as a top pick, citing its robust product pipeline and favorable market position. This upward revision …

Earnings To Watch: Treace Medical Concepts Inc (TMCI) Q2 2026 -- GF Value Sees 49% Upside

Once Upon a Farm Q2 2026 Earnings: 42% Sales Growth Comes With Margin Pressure

ALX Oncology (NASDAQ:ALXO) Issues Earnings Results

Dickson Concepts Wins Strong Shareholder Backing at 2026 AGM

CG Oncology (CGON) Earnings Date and Reports 2026

Once Upon A Farm (OFRM) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates